{"entity":{"id":"nct00024167","kind":"trial","name":"Chemotherapy With or Without Strontium-89 in Treating Patients With Prostate Cancer","aka":[],"tldr":"A phase 3 trial of Docetaxel, Doxorubicin, Estramustine, Prednisone, Vinblastine and Dexamethasone in Prostate cancer, run by M.D. Anderson Cancer Center, recorded as terminated on the registry.","summary":"Chemotherapy With or Without Strontium-89 in Treating Patients With Prostate Cancer is a phase 3 interventional study registered as NCT00024167 by M.D. Anderson Cancer Center, with 265 participants recorded, started 2002-04 and due to reach its primary completion in 2014-09. Interventions recorded: Docetaxel, Doxorubicin hydrochloride, Estramustine phosphate sodium, Ketoconazole, Prednisone, Vinblastine, Strontium chloride Sr 89, Dexamethasone. Conditions recorded: Prostate Cancer.\n\nLinked to the drug Estramustine because the registry names it among its interventions and Prostate cancer among its conditions. Registry record only: no result has been read by an editor.","asOf":"2026-09-24","links":[{"label":"ClinicalTrials.gov NCT00024167","url":"https://clinicaltrials.gov/study/NCT00024167"}],"tags":["pipeline","ctgov-ingest"],"related":[],"cancers":["prostate"],"sections":[],"technologies":[],"targets":[],"drugs":["docetaxel","doxorubicin","estramustine","prednisone","vinblastine","dexamethasone"],"companies":[],"institutions":[],"pathways":[],"terms":[],"trials":[],"people":[],"bottlenecks":[],"keyPapers":[],"journals":[],"dependsOn":[],"notes":[],"nct":"NCT00024167","phase":"3","setting":"A Prospective Randomized Phase III, Trial Comparing Consolidation Therapy With or Without Strontium-89 Following Induction Chemotherapy in Androgen-Independent Prostate Cancer","sponsor":"M.D. Anderson Cancer Center","started":"2002-04","yearReported":2016,"enrolled":265,"enrolledBasis":"registry","outcomes":[{"endpoint":"Overall Survival From Randomization","primary":true,"unit":"months","arms":[{"name":"Induction Treatment + Strontium-89","n":65,"value":24.2,"note":"95% CI 19.8 to 29.8; Figures from the ClinicalTrials.gov results section (first posted 2016-03-22), not from a publication"},{"name":"Induction Treatment + No Strontium-89","n":62,"value":22.8,"note":"95% CI 17.7 to 27.7"}],"source":"https://clinicaltrials.gov/study/NCT00024167?tab=results"}]},"route":"/trials/nct00024167/","neighbours":{"cancer":[{"id":"prostate","kind":"cancer","name":"Prostate cancer","route":"/cancers/prostate/"}],"drug":[{"id":"dexamethasone","kind":"drug","name":"Dexamethasone","route":"/drugs/dexamethasone/"},{"id":"docetaxel","kind":"drug","name":"Docetaxel","route":"/drugs/docetaxel/"},{"id":"doxorubicin","kind":"drug","name":"Doxorubicin","route":"/drugs/doxorubicin/"},{"id":"estramustine","kind":"drug","name":"Estramustine","route":"/drugs/estramustine/"},{"id":"prednisone","kind":"drug","name":"Prednisone","route":"/drugs/prednisone/"},{"id":"vinblastine","kind":"drug","name":"Vinblastine","route":"/drugs/vinblastine/"}]}}